Can a common antiviral save lives in advanced HIV?
NCT ID NCT07379203
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether valganciclovir, a drug that stops CMV from multiplying, can safely lower CMV levels in the blood of people with advanced HIV. About 130 adults and adolescents with very weak immune systems will be randomly assigned to take either valganciclovir or a placebo daily for 4 weeks, while continuing standard HIV care. Researchers will monitor side effects and check if the drug reduces hospitalizations or deaths.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Valganciclovir
What this could lead to
If it works, this could point toward a standard treatment to reduce CMV-related deaths in people with advanced HIV.
What could go wrong
This is a phase 2b trial with only 130 participants, so results may not apply broadly. Valganciclovir can cause serious side effects like low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.